Small cell lung cancer (SCLC) is highly malignant,prone to early recurrence and metastasis,and has a poor prognosis.The median survival for extensive stage SCLC (ES-SCLC) with chemotherapy as the main treatment method is only 8 to 12 months.The combined treatment mode of immunotherapy combined with chemotherapy improved the survival of patients with ES-SCLC to a certain extent than before,but two large-scale clinical studies CASPIAN and IMpower133 only improved the survival of less than 3 months.This article will review the current status and research progress of first-line treatment of ES-SCLC.
维普
万方数据